Prelude Q1 net loss $29.5M ($0.63/sh); cash $266.2M funds into 2H2024; on track for data readouts in 2H2022

Prelude Therapeutics Inc

2023-Q1 EPS reported -$0.63

Net loss $29.5M ($0.63/sh) vs $21.3M ($0.47) YoY; R&D expense $22.8M ($16.5M) on increased clinical activity.
Cash & equivalents $266.2M as of March 31, 2022, expected to fund operations into second half 2024.
PRMT5 program (PRT811) expansion cohort data analysis ongoing; next steps decision in 2H2022.
MCL1 inhibitor PRT1419 IV formulation prioritized; combination cohorts expected by mid-2022.
Jane Huang appointed President and CMO effective April 4, 2022; previously CMO Hematology at BeiGene.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.